AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8888464 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirically-derived social support intervention consisting of four standardized face-to-face sessions at two week intervals and telephone contact in the intervening weeks.
Number of subjects: 319
Study 8888464 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 319
Study 2001639 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (points: Hegu, Neiguan, Zusanli and Gongsun bilaterally)
Number of subjects: 36
Study 2001639 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture (control group)
Number of subjects: 36
Study 2001639 — intervention group
Group type: COMPARATOR
Intervention: Pretend acupuncture (control group)
Number of subjects: 36
Study 2001639 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 36
Study 6666217 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 22
Study 6666217 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 22
Study 6666217 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 22
Study 31473690 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement program utilizing resilience theory framework
Number of subjects: 550
Study 31473690 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-reduction measures (e.g., checking air-quality forecasts, limiting outside activities)
Number of subjects: 550
Study 30076988 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle education, stress reduction guided imagery, and lifestyle behavior guided imagery (12-week intervention)
Number of subjects: 0
Study 30076988 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30076988 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 27422893 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 20 mg BID
Number of subjects: 484
Study 27422893 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 30 mg BID
Number of subjects: 484
Study 27422893 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 484
Study 24647431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain (induced by hypertonic saline injection) during bilateral leg squat task
Number of subjects: 15
Study 24647431 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no pain) during isometric tasks
Number of subjects: 15
Study 22851808 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-delayed sleep regimen (23:00 to 07:00)
Number of subjects: 392
Study 22851808 — intervention group
Group type: COMPARATOR
Intervention: Customary sleep regimen (20:30 to 04:30)
Number of subjects: 392
Study 20473057 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 25 mg eq.
Number of subjects: 652
Study 20473057 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 100 mg eq.
Number of subjects: 652
Study 20473057 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 150 mg eq.
Number of subjects: 652
Study 20473057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study 20473057 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (all doses combined)
Number of subjects: 652
Study 18025444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar support group
Number of subjects: 360
Study 18025444 — intervention group
Group type: COMPARATOR
Intervention: Short course only (Control)
Number of subjects: 360
Study 15467555 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned cesarean delivery
Number of subjects: 923
Study 15467555 — intervention group
Group type: COMPARATOR
Intervention: Planned vaginal birth
Number of subjects: 923
Study 11460520 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor XIII
Number of subjects: 0
Study 11460520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9710647 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine examination
Number of subjects: 13
Study 9710647 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 13
Study 8790560 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 10(6) units of recombinant IFN-alpha-2b (rIFN) subcutaneously three times per week for 24 weeks
Number of subjects: 163
Study 8790560 — intervention group
Group type: COMPARATOR
Intervention: 1 x 10(6) units of recombinant IFN-alpha-2b (rIFN) subcutaneously three times per week for 24 weeks
Number of subjects: 163
Study 8790560 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 10(6) units of rIFN
Number of subjects: 163
Study 2691375 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive surgical resection (quadrantectomy) with axillary dissection and radiotherapy (QUART)
Number of subjects: 0
Study 2691375 — intervention group
Group type: COMPARATOR
Intervention: QUART technique (quadrantectomy with axillary dissection and intensive radiotherapy)
Number of subjects: 0
Study 2691375 — intervention group
Group type: COMPARATOR
Intervention: QUART techniques (quadrantectomy and axillary dissection without radiotherapy)
Number of subjects: 0
Study 781661 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinonide ('Metosyn') applied once daily
Number of subjects: 2
Study 781661 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 17-valerate ('Betnovate') applied twice daily
Number of subjects: 2
Study 28919200 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab every 8 weeks
Number of subjects: 2295
Study 28919200 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab every 4 weeks
Number of subjects: 2295
Study 28919200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2295
Study 27555131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu Aura‐i
Number of subjects: 65
Study 27555131 — intervention group
Group type: COMPARATOR
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 65
Study 27555131 — intervention group
Group type: COMPARATOR
Intervention: ILMA
Number of subjects: 65
Study 24972557 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved scissors
Number of subjects: 155
Study 24972557 — intervention group
Group type: COMPARATOR
Intervention: Straight scissors
Number of subjects: 155
Study 22906738 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (IFNβ-1b)
Number of subjects: 0
Study 22906738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20012179 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-determination theory (SDT) based weight management intervention
Number of subjects: 239
Study 20012179 — intervention group
Group type: COMPARATOR
Intervention: General health education program (control)
Number of subjects: 239
Study 18824271 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (EXU; Exubera)
Number of subjects: 580
Study 18824271 — intervention group
Group type: COMPARATOR
Intervention: Short-acting subcutaneous (SC) insulin
Number of subjects: 580
Study 15919435 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus + low-dose Mycophenolate Mofetil (750 mg orally twice a day)
Number of subjects: 30
Study 15919435 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus + low-dose Mycophenolate Mofetil (750 mg orally twice a day) + steroids
Number of subjects: 30
Study 12768289 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid (LA) 28.5 mg and gamma-linolenic acid (GLA) 15.1 mg, treated once daily orally from 3 days before PRK to 1 month after PRK
Number of subjects: 60
Study 12768289 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment with LA and GLA)
Number of subjects: 60
Study 10814990 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8-fold dose of protamine (Group L)
Number of subjects: 28
Study 10814990 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0-fold dose of protamine (Group H)
Number of subjects: 28
Study 8861577 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized ultrasound examination
Number of subjects: 29
Study 8861577 — intervention group
Group type: COMPARATOR
Intervention: Standard X-rays of the shoulder
Number of subjects: 29
Study 1519637 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120, 240, 360, or 480 mg)
Number of subjects: 390
Study 1519637 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg/day for 2 weeks, 360 mg/day for 2 weeks, and then 540 mg/day for 2 weeks)
Number of subjects: 390
Study 1519637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 6501124 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 2 g latamoxef (moxalactam)
Number of subjects: 20
Study 6501124 — intervention group
Group type: COMPARATOR
Intervention: Three doses of latamoxef (moxalactam)
Number of subjects: 20
Study 30277420 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia/β-alanine (HB)
Number of subjects: 38
Study 30277420 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine (BA)
Number of subjects: 38
Study 30277420 — intervention group
Group type: COMPARATOR
Intervention: Normoxia/placebo (NP)
Number of subjects: 38
Study 30277420 — intervention group
Group type: COMPARATOR
Intervention: Normobaric hypoxia/placebo (HP)
Number of subjects: 38
Study 30277420 — intervention group
Group type: COMPARATOR
Intervention: Normoxia/β-alanine (NB)
Number of subjects: 38
Study 30281397 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation (MOP) with fixed appliance (Gemini 3M) every 28 days
Number of subjects: 60
Study 30281397 — intervention group
Group type: COMPARATOR
Intervention: Control group with identical brackets without MOP
Number of subjects: 60
Study 26936194 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive care
Number of subjects: 281
Study 26936194 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary care
Number of subjects: 281
Study 26936194 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 281
Study 25233856 — intervention group
Group type: EXPERIMENTAL
Intervention: TRK‐100STP 60 μg b.i.d.
Number of subjects: 750
Study 25233856 — intervention group
Group type: EXPERIMENTAL
Intervention: TRK‐100STP 120 μg b.i.d.
Number of subjects: 750
Study 25233856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study 22336172 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of rye bread (99 g/d to 198 g/d)
Number of subjects: 63
Study 22336172 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of rye bread with plant sterols
Number of subjects: 63
Study 21163113 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg to 120 mg once daily
Number of subjects: 215
Study 21163113 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg once daily
Number of subjects: 215
Study 21163113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 21163113 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 215
Study 18274211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention for 12 weeks
Number of subjects: 147
Study 18274211 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 147
Study 16245485 — intervention group
Group type: EXPERIMENTAL
Intervention: Pointing movements with 8 stimulus sizes (2.5 cm to 20 cm) and 32 durations (0.2 s to 1.75 s)
Number of subjects: 0
Study 16245485 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing movements with 8 stimulus sizes (2.5 cm to 20 cm) and 32 durations (0.2 s to 1.75 s)
Number of subjects: 0
Study 12398872 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) therapy
Number of subjects: 36
Study 12398872 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine, azathioprine and prednisone (Control)
Number of subjects: 36
Study 10464707 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: IFN (alpha Interferon‐1,000,000 U/d), Cyclosporine A (CSA‐1 mg/kg/d intravenous) for 28 days, and GM‐CSF (250/m2/d) until engraftment
Number of subjects: 80
Study 10464707 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: CSA (1 mg/kg/d intravenous) and GM‐CSF
Number of subjects: 80
Study 10464707 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: CSA (1 mg/kg/d orally) and GM‐CSF
Number of subjects: 80
Study 10464707 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D: only GM‐CSF
Number of subjects: 80
Study 10464707 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed GVHD
Number of subjects: 80
Study 10464707 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without GVHD
Number of subjects: 80
Study 10464707 — intervention group
Group type: COMPARATOR
Intervention: Patients with multiple myeloma (MM)
Number of subjects: 80
Study 7717013 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (3 x 60 mg daily)
Number of subjects: 24
Study 7717013 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (3 x 50 mg daily)
Number of subjects: 24
Study 3437274 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial videogame (played singly)
Number of subjects: 160
Study 3437274 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive videogame (played singly)
Number of subjects: 160
Study 3437274 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive videogame (played competitively)
Number of subjects: 160
Study 3437274 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial videogame (played cooperatively)
Number of subjects: 160
Study 3437274 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 160
Study 29924771 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy to achieve LDLC level less than 1.8 mmol/l
Number of subjects: 82
Study 29924771 — intervention group
Group type: COMPARATOR
Intervention: Therapy to achieve LDLC level below 2.6 mmol/l
Number of subjects: 82
Study 27145207 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy food supplementation (50 mg isoflavones or 15 g soy protein in the form of tofu)
Number of subjects: 57
Study 27145207 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low‐fat diet (11.3% of total energy)
Number of subjects: 57
Study 27145207 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 57
Study 24959516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 40
Study 24959516 — intervention group
Group type: COMPARATOR
Intervention: Basic health education (BHE)
Number of subjects: 40
Study 22480863 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-min preoperative home rehabilitation education program 4 weeks prior to TKA
Number of subjects: 243
Study 22480863 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative program)
Number of subjects: 243
Study 20860662 — intervention group
Group type: EXPERIMENTAL
Intervention: VS411-2 formulation (didanosine 400 mg and hydroxyurea 600 mg)
Number of subjects: 0
Study 20860662 — intervention group
Group type: COMPARATOR
Intervention: Commercially available ddI (Videx EC)
Number of subjects: 0
Study 20860662 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea (Hydrea)
Number of subjects: 0
Study 18082885 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital radiation treatment
Number of subjects: 100
Study 19958855 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 8800
Study 19958855 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 8800
Study 19958855 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stent types
Number of subjects: 8800
Study 16226178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent indocyanine green (ICG) angiography
Number of subjects: 120
Study 11688001 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human hemoglobin (rHb1.1)
Number of subjects: 18
Study 11688001 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 18
Study 9230329 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (500 mg twice daily for 10 days)
Number of subjects: 164
Study 8233265 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified estrogens plus methyltestosterone
Number of subjects: 26
Study 8233265 — intervention group
Group type: COMPARATOR
Intervention: Esterified estrogens alone
Number of subjects: 26
Study 3112672 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 315
Study 3112672 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (base)
Number of subjects: 315
Study 3112672 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (stearate)
Number of subjects: 315
Study 3112672 — intervention group
Group type: COMPARATOR
Intervention: No peritreatment antibiotics (from previous study)
Number of subjects: 315
Study 11579306 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and prednisone (double-drug therapy)
Number of subjects: 350
Study 11579306 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus, prednisone, and mycophenolate mofetil (triple-drug therapy)
Number of subjects: 350
Study 30914089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention training (playing electronic musical keyboard, learning simple Spanish, clock‐drawing, psychological intervention) for 2 months
Number of subjects: 133
Study 30914089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention training
Number of subjects: 133
Study 30914089 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cognitive training)
Number of subjects: 133
Study 30333302 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin
Number of subjects: 0
Study 26488615 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed instructions
Number of subjects: 35
Study 26488615 — intervention group
Group type: COMPARATOR
Intervention: Accuracy instructions
Number of subjects: 35
Study 24752880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study 24752880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22248502 — intervention group
Group type: EXPERIMENTAL
Intervention: BEET (140 ml/d of concentrated beetroot juice; 8 mmol/d nitrate)
Number of subjects: 12
Study 22248502 — intervention group
Group type: COMPARATOR
Intervention: PLAC (nitrate-depleted beetroot juice)
Number of subjects: 12
Study 20215360 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU)
Number of subjects: 1717
Study 20215360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1717
Study 20215360 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in boys
Number of subjects: 1717
Study 20215360 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in girls
Number of subjects: 1717
Study 20215360 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estimate of neonatal vitamin A supplementation on mortality
Number of subjects: 1717
Study 17365790 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR therapy
Number of subjects: 24
Study 17365790 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 24
Study 15734603 — intervention group
Group type: COMPARATOR
Intervention: Tibolone 1.25 mg
Number of subjects: 317
Study 15734603 — intervention group
Group type: COMPARATOR
Intervention: Tibolone 2.5 mg
Number of subjects: 317
Study 15734603 — intervention group
Group type: COMPARATOR
Intervention: Tibolone 5.0 mg
Number of subjects: 317
Study 15734603 — intervention group
Group type: COMPARATOR
Intervention: Tibolone 0.625 mg
Number of subjects: 317
Study 15734603 — intervention group
Group type: COMPARATOR
Intervention: Tibolone (all doses)
Number of subjects: 317
Study 11781274 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI-1493 (8 mg/m2 daily for 12 days)
Number of subjects: 12
Study 11781274 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI-1493 (25 mg/m2 daily for 12 days)
Number of subjects: 12
Study 11781274 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI-1493 (both dosages)
Number of subjects: 12
Study 9579005 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing gum (NCG)
Number of subjects: 299
Study 7815681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-liposuction procedure
Number of subjects: 15
Study 2682877 — intervention group
Group type: EXPERIMENTAL
Intervention: Home continuous intravenous infusion chemotherapy (CVI)
Number of subjects: 22
Study 2682877 — intervention group
Group type: COMPARATOR
Intervention: Inpatient continuous intravenous infusion chemotherapy (CVI)
Number of subjects: 22
Study 5354851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate plus succinic acid
Number of subjects: 5
Study 5354851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate plus ascorbic acid
Number of subjects: 5
Study 5354851 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate with ascorbic acid and succinic acid
Number of subjects: 5
Study 5354851 — intervention group
Group type: COMPARATOR
Intervention: Ferrous fumarate (tablets)
Number of subjects: 5
Study 30376388 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage (20 min, twice a week for 12 weeks)
Number of subjects: 36
Study 28439734 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reperfusion (PCI within 12 hours)
Number of subjects: 788
Study 28439734 — intervention group
Group type: COMPARATOR
Intervention: Late reperfusion (PCI between 12 and 48 hours)
Number of subjects: 788
Study 25483979 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day discontinuation of statin treatment
Number of subjects: 34
Study 25483979 — intervention group
Group type: COMPARATOR
Intervention: Continuation of statin treatment
Number of subjects: 34
Study 24085590 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine nasal spray (32.73 mg/mL) at doses of 2 mg and 4 mg
Number of subjects: 12
Study 24085590 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine nasal spray (16.36 mg/mL) at a dose of 1 mg
Number of subjects: 12
Study 24085590 — intervention group
Group type: COMPARATOR
Intervention: Tizanidine oral tablets (4 mg)
Number of subjects: 12